Omeros Corp financial data

Symbol
OMER on Nasdaq
Industry
Pharmaceutical Preparations
Location
201 Elliott Avenue West, Seattle, WA
State of incorporation
WA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 381 % +34.8%
Return On Equity 143 % +164%
Return On Assets -36.2 % -1084%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 57.9M shares -7.82%
Common Stock, Shares, Outstanding 57.9M shares -7.82%
Entity Public Float 328M USD +98.2%
Common Stock, Value, Issued 579K USD -7.8%
Weighted Average Number of Shares Outstanding, Basic 57.9M shares -7.81%
Weighted Average Number of Shares Outstanding, Diluted 62.8M shares +0.17%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 125M USD +11.2%
General and Administrative Expense 48.2M USD -6.42%
Costs and Expenses 173M USD +5.13%
Operating Income (Loss) -173M USD -5.13%
Net Income (Loss) Attributable to Parent -135M USD -773%
Earnings Per Share, Basic -2.31 USD/shares -800%
Earnings Per Share, Diluted 0.65 USD/shares -79.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.52M USD -95%
Cash, Cash Equivalents, and Short-term Investments 123M USD -60.3%
Assets, Current 165M USD -53.1%
Property, Plant and Equipment, Net 1.94M USD +12.9%
Operating Lease, Right-of-Use Asset 15.9M USD -18.1%
Assets 313M USD -36.5%
Accounts Payable, Current 7.72M USD +31.7%
Employee-related Liabilities, Current 6.93M USD -44.8%
Accrued Liabilities, Current 23.2M USD -33.3%
Liabilities, Current 55.6M USD -62.2%
Operating Lease, Liability, Noncurrent 22M USD -23.7%
Retained Earnings (Accumulated Deficit) -879M USD -18.1%
Stockholders' Equity Attributable to Parent -154M USD -1005%
Liabilities and Equity 313M USD -36.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -41.8M USD -124%
Net Cash Provided by (Used in) Financing Activities 98.4M USD
Net Cash Provided by (Used in) Investing Activities -61.9M USD +65.9%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 57.9M shares -7.82%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5.27M USD +26.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.6M USD -53.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 7.15M USD -9.85%
Deferred Tax Assets, Valuation Allowance 238M USD +17.4%
Deferred Tax Assets, Gross 282M USD +15.8%
Operating Lease, Liability 25.9M USD -22.6%
Depreciation 200K USD 0%
Payments to Acquire Property, Plant, and Equipment 58K USD
Lessee, Operating Lease, Liability, to be Paid 28.4M USD -19.1%
Property, Plant and Equipment, Gross 12.7M USD +8.14%
Operating Lease, Liability, Current 3.89M USD -15.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 7.09M USD +0.81%
Lessee, Operating Lease, Liability, to be Paid, Year One 8.53M USD +2.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.42M USD -30.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 6.87M USD -3.08%
Deferred Tax Assets, Operating Loss Carryforwards 95.2M USD +10.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Unrecognized Tax Benefits 1.97M USD +827%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.95M USD -13.4%
Operating Lease, Payments 1.82M USD +1.97%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 204K USD +9.68%
Share-based Payment Arrangement, Expense 10.8M USD -12%
Interest Expense 28.6M USD -9.85%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%